Please assess the completion status of the following clinical trial:

Trial Title: Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Subject is willing to participate and provide informed consent~* Subject is considered reliable and capable of adhering to the protocol per the judgment of the Investigator~* Subjects in group D must exhibit good organ reserves (within prior 4 weeks) defined as:~  1. Estimated GFR \>35 (formula),~ 2. Platelet count \>65 K/uL,~ 3. Hemoglobin \>10.5 grams/dL~ 4. Total bilirubin \<2.0 mg/dL~* Minimum age 18 years old~* Body mass index (BMI) between 18 and 35 kg/m2~* For cohort D (antiphospholipid antibodies) a. Subjects in group D must have at least one positive antiphospholipid antibody within the last 8 weeks and/or previous confirmed antibodies (2 or more occasions at least 12 weeks apart) : i. Positive lupus anticoagulant ii. anticardiolipin antibody IgM or IgG (\>40U GPL) iii. anti-β2 Glycoprotein1 antibody titer (\>35 units)~Exclusion Criteria~* Pregnant. If female of child-bearing age, negative urinary pregnancy test prior to dosing of quercetin or isoquercetin~* No history of malabsorptive gastrointestinal disorder~* Currently taking aspirin, NSAIDS, warfarin, low-molecular weight heparin or other anticoagulants (such as direct thrombin inhibitors or factor X inhibitors)~  a. Note: Study subjects taking aspirin or NSAIDS, if treating physician concurs, are permitted to enroll if plan to hold for aspirin 10 days or NSAIDS 24 hours prior to dosing of quercetin/isoquercetin~* Prescribed niacin for hyperlipidemia~* Known HIV~* History of sensitivity or intolerance to flavonoids, niacin or ascorbic acid~* May not have uncontrolled intercurrent illness including, but not limited to ongoing or active infection, hepatitis, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Quercetin (Type: EXPERIMENTAL): Single dose of quercetin with or without ascorbic acid
- Isoquercetin (Type: ACTIVE_COMPARATOR): Single dose of isoquercetin with or without ascorbic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).